ATE389029T1 - Protease assay zur kontrolle medikamentöser therapie - Google Patents
Protease assay zur kontrolle medikamentöser therapieInfo
- Publication number
- ATE389029T1 ATE389029T1 AT02790358T AT02790358T ATE389029T1 AT E389029 T1 ATE389029 T1 AT E389029T1 AT 02790358 T AT02790358 T AT 02790358T AT 02790358 T AT02790358 T AT 02790358T AT E389029 T1 ATE389029 T1 AT E389029T1
- Authority
- AT
- Austria
- Prior art keywords
- drug therapy
- control drug
- protease assay
- present
- concentration
- Prior art date
Links
- 108091005804 Peptidases Proteins 0.000 title 1
- 239000004365 Protease Substances 0.000 title 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title 1
- 238000003556 assay Methods 0.000 title 1
- 238000002651 drug therapy Methods 0.000 title 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000004166 bioassay Methods 0.000 abstract 1
- 238000001952 enzyme assay Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001177 retroviral effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
- G01N2333/161—HIV-1, HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p.7, p6, p66/68, p51/52, p31/34, p32, p40
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33111701P | 2001-11-08 | 2001-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE389029T1 true ATE389029T1 (de) | 2008-03-15 |
Family
ID=23292681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02790358T ATE389029T1 (de) | 2001-11-08 | 2002-11-08 | Protease assay zur kontrolle medikamentöser therapie |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7320878B2 (de) |
| EP (1) | EP1446498B1 (de) |
| JP (1) | JP2005513420A (de) |
| AT (1) | ATE389029T1 (de) |
| CA (1) | CA2466497A1 (de) |
| DE (1) | DE60225587T2 (de) |
| ES (1) | ES2302860T3 (de) |
| WO (1) | WO2003040390A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014030A1 (en) * | 2002-07-18 | 2004-01-22 | Lili Arabshahi | Enzymatic assay of HIV protease inhibitors |
| CN1874789A (zh) * | 2003-09-23 | 2006-12-06 | 光科学公司 | 用于光动力疗法的缀合物 |
| US20060199221A1 (en) * | 2005-03-07 | 2006-09-07 | Samad Talebpour | Correction for temperature dependence assays |
| WO2007079392A2 (en) * | 2005-12-30 | 2007-07-12 | The Trustees Of Columbia University In The City Of New York | Real-time assays of neuro-humoral to assess cardiovascular stress |
| US8185319B2 (en) * | 2006-01-19 | 2012-05-22 | Novx Systems Canada Inc. | Method of compensation of dose-response curve of an assay for sensitivity to perturbing variables |
| GB201402132D0 (en) * | 2014-02-07 | 2014-03-26 | South African Nuclear Energy | A method of producing ethylenedicysteine deoxyglucosamine (ECDG) or a salt thereof and its application in a kit |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1185881A (en) * | 1982-02-01 | 1985-04-23 | Jacques Degelaen | ENZYMATIC PROCESS FOR THE DETERMINATION OF .beta.-LACTAM ANTIBIOTICS |
| DE3531778A1 (de) * | 1985-09-06 | 1987-03-12 | Behringwerke Ag | Verfahren zur bestimmung von proteaseinhibitoren |
| EP0428000A1 (de) | 1989-11-03 | 1991-05-22 | Abbott Laboratories | Fluorogene Substrate zum Nachweis von proteolytischer Enzymaktivität |
| US5235039A (en) | 1991-06-10 | 1993-08-10 | Eli Lilly And Company | Substrates for hiv protease |
| JP3657002B2 (ja) * | 1992-08-25 | 2005-06-08 | ジー．ディー．サール アンド カンパニー | レトロウイルスプロテアーゼ阻害剤として有用なα−およびβ−アミノ酸ヒドロキシエチルアミノスルホンアミド |
| US5576177A (en) * | 1994-03-09 | 1996-11-19 | St. Jude Children's Research Hospital | Bioassay for reverse transcriptase inhibitors |
| ES2177922T3 (es) | 1996-01-26 | 2002-12-16 | Virco Bvba | Metodo de valoracion la quimioterapia de pacientes hiv-positivos basado en la sensibilidad fenotipica a los farmacos de las cepas de hiv delpaciente. |
| PL328068A1 (en) | 1996-01-29 | 1999-01-04 | Virologic | Compositions for and methods of determining susceptibility to and immunity against an antiviral drug and selecting appropriate antiviral drug |
| JP3768304B2 (ja) | 1996-10-07 | 2006-04-19 | 株式会社松井製作所 | 冷媒設備用のバルブ |
| US6243980B1 (en) * | 1997-03-07 | 2001-06-12 | Tropix, Inc. | Protease inhibitor assay |
| US6017723A (en) * | 1998-03-27 | 2000-01-25 | Long Island Jewish Medical Center | Method for isolating inhibitors of protease activity |
| CA2228821A1 (en) | 1998-04-16 | 1999-10-16 | Zhibo Gan | Pin method for measuring bioactive substance |
| JP4776775B2 (ja) | 1998-06-23 | 2011-09-21 | アメリカ合衆国 | Ｈｉｖ感染哺乳動物を治療するための医薬組成物 |
| AU2001233513A1 (en) | 2000-02-04 | 2001-08-14 | K.U. Leuven Research And Development | Hiv-1 resistance assay |
| EP1332231B1 (de) | 2000-04-18 | 2008-08-13 | Virco Bvba | Methode zur bestimmung der resistenz gegen medikamente |
| JP2004510961A (ja) | 2000-09-15 | 2004-04-08 | ビルコ・ビーブイビーエイ | 疾患の処置のための薬物療法を最適化するシステムおよび方法 |
| AU2305202A (en) | 2000-11-10 | 2002-05-21 | Bioalliance Pharma | Novel method for analysing phenotypic characteristics of human immunodeficiency virus (hiv) |
-
2002
- 2002-11-08 CA CA002466497A patent/CA2466497A1/en not_active Abandoned
- 2002-11-08 US US10/494,903 patent/US7320878B2/en not_active Expired - Fee Related
- 2002-11-08 ES ES02790358T patent/ES2302860T3/es not_active Expired - Lifetime
- 2002-11-08 EP EP02790358A patent/EP1446498B1/de not_active Expired - Lifetime
- 2002-11-08 AT AT02790358T patent/ATE389029T1/de not_active IP Right Cessation
- 2002-11-08 WO PCT/EP2002/012631 patent/WO2003040390A2/en not_active Ceased
- 2002-11-08 DE DE60225587T patent/DE60225587T2/de not_active Expired - Fee Related
- 2002-11-08 JP JP2003542636A patent/JP2005513420A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE60225587D1 (de) | 2008-04-24 |
| WO2003040390A2 (en) | 2003-05-15 |
| US20050221286A1 (en) | 2005-10-06 |
| WO2003040390A3 (en) | 2003-09-25 |
| JP2005513420A (ja) | 2005-05-12 |
| ES2302860T3 (es) | 2008-08-01 |
| EP1446498A2 (de) | 2004-08-18 |
| DE60225587T2 (de) | 2009-04-02 |
| US7320878B2 (en) | 2008-01-22 |
| CA2466497A1 (en) | 2003-05-15 |
| EP1446498B1 (de) | 2008-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE377654T1 (de) | Ubiquitin-ligase-assay | |
| EP1411118A4 (de) | Zellproliferationsinhibitoren mit anti-glypican-3-antikörper | |
| ATE485366T1 (de) | Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau | |
| DE50211045D1 (de) | Medizinische aerosolformulierungen | |
| TR199800046A2 (xx) | Aktif maddeler yarat�lmas� i�in n�kleik asit olu�umu. | |
| DE69635671D1 (de) | Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren | |
| EP1302542A4 (de) | Neues, physiologisch aktives peptid und dessen verwendung | |
| DE60126970D1 (de) | Kristallstruktur von bace und verwendungen dafür | |
| BR0014282A (pt) | Vacinas | |
| ECSP045520A (es) | Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos | |
| WO2003000853A3 (en) | Protein aggregation assays and uses thereof | |
| DE60225587D1 (de) | Protease assay zur kontrolle medikamentöser therapie | |
| ATE220110T1 (de) | Assays und reaganzien zur identifizierung von fungiziden wirkstoffen und ihre verwendungen | |
| DK1353948T3 (da) | Oplöselige biologiske analoge til bata-amyloidpeptid | |
| PT1147420E (pt) | Inibidor de tripsina urinario para o diagnostico da sida | |
| ATE291586T1 (de) | Humanes antibiotisches protein | |
| DK1343896T3 (da) | Lille syreoplöseligt sporeprotein og anvendelser deraf | |
| BR0213183A (pt) | Uso de ativadores gp130 em neuropatia diabética | |
| DK1331940T3 (da) | Anvendelse af det lange pentraxin PTX3 til behandling af sygdomme forårsaget af ændret aktivering af vækstfaktoren FGF-2 | |
| DE50113974D1 (de) | Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen | |
| ATE353642T1 (de) | Verwendung von hypoestoxiden als antiparasitäre mittel | |
| DE60042753D1 (de) | Von antibiotika | |
| ATE376840T1 (de) | Gentherapeutika | |
| DE60128950D1 (de) | Proteine aus yaba monkey tumor virus mit modulatorischer aktivität | |
| ATE315093T1 (de) | Hcv ns2/3 fragmente und ihre verwendungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |